2 items across 2 digests
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced death risk by 34% in a late-stage trial conducted in China. This significant efficacy result could accelerate regulatory approval and market adoption for this cancer treatment.
AstraZeneca's stock jumped after its experimental drug reduced flare-ups for chronic obstructive pulmonary disease patients, succeeding where rival treatments failed. This breakthrough could capture significant market share in the COPD treatment market worth billions annually.
DailySand